Are Mammaprint and OncotypeDx as useful in stratifying risk in patients with early stage HR+, HER2 negative lobular carcinomas, as in those with ductal carcinomas?

OncotypDX is not very useful in stratifying patients with early stage HR+ HER 2 negative invasive lobular carcinoma. Several studies (MD Anderson, Penn State) have shown that only 1-2 % of invasive ILC cancers are classified as High risk therefore receiving strong recommendation for chemotherapy. Si...